Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Erika Huber"'
Autor:
Annika Erika Huber, Mohammad Haft-Javaherian, Maxime Berg, Asheesh Lanba, Sylvie Lorthois, Taryn L. Bauerle, Nozomi Nishimura
The xylem network, the water conduction system in wood determines the ability of trees to avoid hydraulic failure during drought stress. The capability to withstand embolisms, disruptions of the water column by gas bubbles that contribute to hydrauli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f026da49ee0c46c7d716757c69cbc5e1
https://doi.org/10.1101/2023.01.10.523508
https://doi.org/10.1101/2023.01.10.523508
Autor:
Zachary Kincaid, Kakajan Komurov, Y Khalifa, J Leddonne, Erika Huber, Harry Leighton Grimes, Z Siddiqui, Mohammad Azam, Sara Rohrabaugh, Meenu Kesarwani
Publikováno v:
Leukemia
Both membrane-proximal and truncation mutations in CSF3R have recently been reported to drive the onset of chronic neutrophilic leukemia (CNL). Here we show that although truncation mutation alone can not induce leukemia, both proximal and compound m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45bd3a9c15c11159d13727ed7c05cd0d
http://europepmc.org/articles/PMC5537052
http://europepmc.org/articles/PMC5537052
Autor:
Jose A. Cancelas, H. Leighton Grimes, Sara Rohrabaugh, Muhammad F. Bouso, James C. Mulloy, Zachary Kincaid, Zain Siddiqui, Ahmed Gomaa, Mohammad Azam, Ming Xu, Meenu Kesarwani, Erika Huber, Kakajan Komurov, Tahir Latif
Publikováno v:
Nature medicine
Tyrosine-kinase inhibitor (TKI) therapy for human cancers is not curative, and relapse occurs owing to the continued presence of tumor cells, referred to as minimal residual disease (MRD). The survival of MRD stem or progenitor cells in the absence o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e09f3e7a3944083bb501ddb818165d7
https://pubmed.ncbi.nlm.nih.gov/28319094
https://pubmed.ncbi.nlm.nih.gov/28319094
Autor:
Erika Huber, Jarek Meller, Neil P. Shah, Zachary Kincaid, Meenu Kesarwani, Mohammad Azam, Yi Zheng, Chris R. Evelyn, Jacek Biesiada, Mahendra Thapa, Mark Rance
Publikováno v:
Scientific Reports
Emergence of genetic resistance against kinase inhibitors poses a great challenge for durable therapeutic response. Here, we report a novel mechanism of JAK2 kinase inhibition by fedratinib (TG101348) that prevents emergence of genetic resistance. Us
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd102309d7c2904c17fe75d116bee1b5
The discovery of BCR/ABL as a driver oncogene in chronic myeloid leukemia (CML) resulted in the development of Imatinib, which, in fact, demonstrated the potential of targeting the kinase in cancers by effectively treating the CML patients. This obse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e27c0db1780527f58ffc8f0de5ada59
https://europepmc.org/articles/PMC4362691/
https://europepmc.org/articles/PMC4362691/
Publikováno v:
Blood. 128:3137-3137
Essential thrombocythemia (ET) is a myeloproliferative neoplasm that is characterized by pathological overproduction of platelets with an increased risk of thromboembolic events, progression to myelofibrosis and leukemic transformation. Mutations of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2d8f753127d1f3205ffecc80f425b41f
https://doi.org/10.1182/blood.v128.22.3137.3137
https://doi.org/10.1182/blood.v128.22.3137.3137
Autor:
Mohammad Azam, Ahmed Ramadan Gomma, Sara Rohrabaugh, Erika Huber, Meenu Kesarwani, Zachary Kincaid, H. Leighton Grimes
Publikováno v:
Blood. 128:3056-3056
Disclosures No relevant conflicts of interest to declare.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e6ec701e8204a14cc0a5d3b2dff34e85
https://doi.org/10.1182/blood.v128.22.3056.3056
https://doi.org/10.1182/blood.v128.22.3056.3056
Autor:
Zachary Kincaid, Mohammad Azam, H. Leighton Grimes, Sara Rohrabaugh, Meenu Kesarwani, Erika Huber
Publikováno v:
Blood. 128:632-632
Disclosures No relevant conflicts of interest to declare.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::da52fa7b52fa8e00486ab6d09104ebbe
https://doi.org/10.1182/blood.v128.22.632.632
https://doi.org/10.1182/blood.v128.22.632.632
Publikováno v:
Blood. 122:5023-5023
A recent discovery of secondary mutations in the kinase domain of Fms-like tyrosine kinase 3 (FLT3) targeted by kinase inhibitor AC220 (quizartinib) established it as a relevant target in acute myeloid leukemia (AML). However, at the same time these
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::312a3e5f224e49d2e7978b7a1edb317a
https://doi.org/10.1182/blood.v122.21.5023.5023
https://doi.org/10.1182/blood.v122.21.5023.5023
Autor:
Thomas Stoll, Erika Huber, Stefan Bachmann, Hans-Ruedi Baumeler, Stefan Mariacher, Martin Rutz, Werner Schneider, Hans Spring, Andr Aeschlimann, Gerold Stucki, Werner Steiner
Publikováno v:
Spine (03622436); Dec2004, Vol. 29 Issue 24, p2851-2855, 5p